The ASX is tracking negatively so far, down by 0.3 per cent at midday, with the biggest gainers being the real estate and healthcare sectors.
In ASX news, Imagion Biosystems (IBX) has initiated plans to close its clinical study after achieving its enrolment target. The company has enrolled 13 patients in its phase one clinical trial, which will use the company’s nanoparticle technology to alter how MRIs can detect cancers.
The company plans to publish those results soon before using the data to lodge an investigational new drug application by early 2024. Imagion shares climbed nearly 42 per cent, trading at 1.7 cents.
Aurumin (AUN) has announced plans to drill four diamond drill holes at its Mt Palmer project in Western Australia. The 1000-metre program will aim to target lithium-bearing pegmatites. Company shares last traded at 4 cents.
Bod Science (BOD) has joined forces with Antah Group to commercialise medical cannabis products in Malaysia. Through clinical trials, the two companies aim to introduce and register medicinal cannabis in Malaysian health care. Once the trials are complete, Antah will have exclusive use of Bod’s product for sales and distribution. BOD slumped 2 per cent to 4.8 cents.
Sultan Resources (SLZ) has entered into a joint venture agreement with Rio Tinto’s (RIO) subsidiary, Rio Tinto Exploration (RTX). The deal would allow Sultan to continue the exploration of Kulin Hill at its Lake Grace tenure in WA. The company’s shares last traded 4.5 cents a share.